Search research articles
Contact Us
Filters
Showing results (11-20 of 82) with videos related to
Page
of 9
Sort By:
The Oncologist
|
February 17, 2026
Impact of immune checkpoint inhibition on ovarian reserve
Elizabeth I Buchbinder, Zihe Song, Justine V Cohen, et al.
Cancer Immunology Research
|
June 1, 2023
Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Xiaoyu Li, Jingjing Li, Yue Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
Lucia Jilaveanu, Christopher Zito, Sandra J Lee, et al.
Cell Host & Microbe
|
January 22, 2009
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene
Yichao Wu, Francisco Navarro, Ashish Lal, et al.
Blood
|
October 24, 2002
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic
Dong Zhang, Premlata Shankar, Zhan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2013
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
Ronald S Go, Sandra J Lee, Donghoon Shin, et al.
Journal of the National Cancer Institute
|
February 14, 2019
Cancer Outcomes in DCIS Patients Without Locoregional Treatment
Marc D Ryser, Donald L Weaver, Fengmin Zhao, et al.
Cancer
|
December 27, 2017
Distinguishing between CISNET model results versus CISNET models
Donald A Berry, Harry J de Koning, Sandra J Lee, et al.
Leukemia Research
|
June 19, 2004
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group
William R Friedenberg, Martin S Tallman, Isadore Brodsky, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 82) with videos related to
Sort By:
Page
of 9
The Oncologist
|
February 17, 2026
Impact of immune checkpoint inhibition on ovarian reserve
Elizabeth I Buchbinder, Zihe Song, Justine V Cohen, et al.
Cancer Immunology Research
|
June 1, 2023
Granulocyte-Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Xiaoyu Li, Jingjing Li, Yue Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
Lucia Jilaveanu, Christopher Zito, Sandra J Lee, et al.
Cell Host & Microbe
|
January 22, 2009
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene
Yichao Wu, Francisco Navarro, Ashish Lal, et al.
Blood
|
October 24, 2002
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic
Dong Zhang, Premlata Shankar, Zhan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
Keith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2013
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
Ronald S Go, Sandra J Lee, Donghoon Shin, et al.
Journal of the National Cancer Institute
|
February 14, 2019
Cancer Outcomes in DCIS Patients Without Locoregional Treatment
Marc D Ryser, Donald L Weaver, Fengmin Zhao, et al.
Cancer
|
December 27, 2017
Distinguishing between CISNET model results versus CISNET models
Donald A Berry, Harry J de Koning, Sandra J Lee, et al.
Leukemia Research
|
June 19, 2004
Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group
William R Friedenberg, Martin S Tallman, Isadore Brodsky, et al.
Page
of 9